Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Caribou Biosciences, Inc.NASDAQ: CRBU

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses dips below year-ago levels

Q1 FY2026 operating expenses of $28.03M fell 35.6% year over year, behind the +26.8% change in trailing-twelve-month operating expenses. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.

Context

  • Operating expenses amounted to 1287.8% of revenue in FY2025, down 440.0 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -35.6% toward the trailing-twelve-month pace of +26.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.03M-13.5% QoQ
Last fiscal yearDec 2025
$143.71M-16.8% YoY
LTMMar 2026
$140.97M+26.8% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.6%——
1 year-16.8%——
3-year CAGR+7.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
143.71M USD
Year-over-year change
-16.8%
4-year CAGR
+17.4%

Operating Expenses vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.8% is the 3rd highest of 11, against a peer median of -14.8%.
  • Operating expenses amounts to 1258.3% of revenue for CRBU, versus a peer median of 660.1%.
CRBU Competitors
Operating Expenses for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$140.97M USD+26.8%+7.2%1258.3%
IVAInventiva S.A.FY2025€137.37M EUR+28.7%+22.8%3064.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$128.39M USD-22.9%-11.4%185.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$112.97M USD-32.5%-15.4%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$100.47M USD-31.6%-2.4%600.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$99.7M USD-6.6%-8.1%719.4%
HUMAHumacyte, Inc.LTM Mar 2026$98.8M USD-9.8%+5.9%4900.7%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$87.45M USD+22.4%+33.4%267.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$87.05M USD-28.0%-7.0%308.4%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$86.18M USD-19.9%-10.1%38304.0%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$74.72M USD+140.4%+76.7%—
Peer median (excluding CRBU) —-14.8%-4.7%660.1%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.